Dr. Reddy's Lab announces launch of generic version of NitroDur

Dr. Reddy's Laboratories announced the launch of an authorized generic version of NitroDur (nitroglycerin) Transdermal Infusion System in the U.S. market.

The announcement was made today, 14 April 2020. BSE and NSE are shut today on account of Ambedkar Jayanti. Dr. Reddy's Laboratories rose 3.49% to settle at Rs 3,744.50 yesterday, 13 April 2020.

Dr. Reddy's Laboratories, along with its subsidiaries today announced the launch of authorized generic version of NitroDur (nitroglycerin) Transdermal Infusion System. The combined market for all Nitrogylcerin Transdermal Patch products had U.S. sales of approximately $14.7 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health.

Dr. Reddy's Nitroglycerin Transdermal Infusion System is available in four dosage strengths: 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, and 0.6 mg/hr, each in a box of 30 count.

Separately, Dr. Reddy's Laboratories along with its subsidiaries announced the launch of Amphetamine Sulfate Tablets USP, a therapeutic equivalent generic version of Evekeo (amphetamine sulfate) Tablets approved by the U.S. Food and Drug Administration (USFDA). Amphetamine Sulfate Tablets, USP is a Schedule II drug.

The Evekeo brand and generic had U.S. sales of approximately $38 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health. Dr. Reddy's Amphetamine Sulfate Tablets USP are available in 5 mg and 10 mg dose in bottle count sizes of 100.

Dr. Reddy's Laboratories is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Powered by Capital Market - Live News